Indolent B-cell non-Hodgkin lymphoma

Indolent B-cell non-Hodgkin lymphoma refers to a heterogeneous group of slow-growing, low-grade malignancies originating from mature B lymphocytes within the lymphatic and hematopoietic systems

Indolent B-cell non-Hodgkin lymphoma refers to a heterogeneous group of slow-growing, low-grade malignancies originating from mature B lymphocytes within the lymphatic and hematopoietic systems

Indolent B-cell non-Hodgkin lymphoma refers to a heterogeneous group of slow-growing, low-grade malignancies originating from mature B lymphocytes within the lymphatic and hematopoietic systems Clinically, they follow an insidiously progressive, relapsing course often marked by extended periods of asymptomatic disease, although patients remain at risk for cytopenias, disease-related complications, or histologic transformation into aggressive lymphoma

Commonly affecting older adults, representative subtypes encompass follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, and small lymphocytic lymphoma Pathophysiologically, these neoplasms arise from dysregulated lymphoid proliferation and impaired apoptosis, characteristically presenting with painless, fluctuating lymphadenopathy, splenomegaly, or bone marrow infiltration

Commonly affecting older adults, representative subtypes encompass follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, and small lymphocytic lymphoma Pathophysiologically, these neoplasms arise from dysregulated lymphoid proliferation and impaired apoptosis, characteristically presenting with painless, fluctuating lymphadenopathy, splenomegaly, or bone marrow infiltration Clinically, they follow an insidiously progressive, relapsing course often marked by extended periods of...

Pathophysiologically, these neoplasms arise from dysregulated lymphoid proliferation and impaired apoptosis, characteristically presenting with painless, fluctuating lymphadenopathy, splenomegaly, or bone marrow infiltration

Clinically, they follow an insidiously progressive, relapsing course often marked by extended periods of asymptomatic disease, although patients remain at risk for cytopenias, disease-related complications, or histologic transformation into aggressive lymphoma